Effect of Punarnavadi Guggulu as a treatment of symptoms occuring before menses

Open Labeled Single Arm Clinical Trail on Punarnavadi Guggulu in the management of Premenstrual Syndrome

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/03/032219

Enrollment

Registered

2021-03-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: Z659- Problem related to unspecified psychosocial circumstances

Interventions

Intervention1: Punarnavadi Guggulu: 4 tablets (500 mg each) twice a day with luke warm water After meal for 2 cycles and one cycle will be observed without intervention Control Intervention1: not appl

Eligibility

Inclusion criteria

Inclusion criteria: Age 18-40 years Irrespective of marrital status Regular cycle Symptoms should appear at definite time in luteal phase of the cycle

Exclusion criteria

Exclusion criteria: Women aged below 18 and above 40 years Diagnosed psychiatric disorder Irregular cycle Any organic pelvic pathology Any known major systemic illness Diabetes PCOS Metrorrhagia symptoms should not persist after 5 days of menstrual cycle symptoms shuold not reoccur within the 1st 13 days

Design outcomes

Primary

Measure	Time frame
To subside premenstrual symptomsTimepoint: 30 days	—

Secondary

Measure	Time frame
relief in the symptoms of dysmenorrheaTimepoint: 30 days	—

Countries

India

Contacts

Public ContactDr Manjusha Karkare

Parul Institute of Ayurveda

mrkarkare@gmail.com9422515717

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026